Drug resistant Plasmodium falciparum malaria Artemisinin resistance K-
Conditions
Interventions
Patients with uncomplicated Plasmodium falciparum malaria treated with supervised mefloquine-
artesunate for 3 days and followed up for 42 days between the years 2003-
2013.
Treatment
Retrospective cohort of patients with uncomplicated Plasmodium falciparum
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
0 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Non pregnant patients of any age and sex who received treatment for uncomplicated malaria between January 2003 to December 2013 • Symptomatic of malaria infection, i.e. history of fever or tympanic temperature ≥37.5°c • Microscopically confirmed asexual stages of P. falciparum ≥ 5/500 WBC (alone or mixed with non- P. falciparum species) • Received fully supervised treatment of mefloquine-artesunate
Exclusion criteria
Exclusion criteria: • Pregnant woman • P. falciparum asexual stage parasitaemia greater than or equal to 4% red blood cells (175 000/µL). • Signs or symptoms indicative of severe malaria: • Mefloquine treatment within 60 days of current episode of malaria • Splenectomy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Day-42 PCR adjusted cure rate 42 days Asexual parasitaemia by microscopy | — |
Secondary
| Measure | Time frame |
|---|---|
| Day-3 positivite for asexual parasitaemia day-3 Asexual parasitaemia by microscopy | — |
Countries
Thailand
Contacts
Public ContactAung Pyae Phyo
Shoklo Malaria Research Unit
Outcome results
None listed